Cooley LLP advised the underwriters on the offering.
The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised €502M ($557M) in a global offering on the Nasdaq Stock Exchange and Euronext Brussels.
The offering, a private placement in Europe as well as a public offering in the US and other countries outside of Europe, consisted of (i) a public offering of 2,010,057 ADSs in the United States and certain other countries outside the European Economic Area (EEA) at a price to the public of $121.00 and (ii) a concurrent private placement of 2,589,943 of ordinary shares in the EEA at an offering price of €109.18.
Morgan Stanley, Cowen, BofA Securities and Evercore acted as joint bookrunning managers for the offering. Kempen acted as lead manager for the offering and Wolfe Capital Markets and Advisory acted as co-manager.
The Cooley team was led by Div Gupta (Picture), Rich Segal, Brent Siler and included Esther Cho, Francis Cullo, Asher Herzog, Madison Jones, Asheley Walker, Bill Christiansen, Ivor Elrifi, William Corcoran, Stephanie Gentile, Rick Jantz, Kenneth Krisko, Natasha Leskovsek, Philip Mitchell, Aaron Nudelman, DéJeune O’Garro, Matthew Pavao, Rebecca Ross, Jennifer Shanley and Francis Wheeler.
Involved fees earner: Esther Cho – Cooley LLP; Bill Christiansen – Cooley LLP; William Corcoran – Cooley LLP; Francis Cullo – Cooley LLP; Ivor Elrifi – Cooley LLP; Stephanie Gentile – Cooley LLP; Div Gupta – Cooley LLP; Asher Herzog – Cooley LLP; Rick Jantz – Cooley LLP; Madison Jones – Cooley LLP; Kenneth Krisko – Cooley LLP; Natasha Leskovsek – Cooley LLP; Phil Mitchell – Cooley LLP; Aaron Nudelman – Cooley LLP; DéJeune O’Garro – Cooley LLP; Matthew Pavao – Cooley LLP; Rebecca Ross – Cooley LLP; Rich Segal – Cooley LLP; Jennifer Shanley – Cooley LLP; Brent Siler – Cooley LLP; Francis Wheeler – Cooley LLP;
Law Firms: Cooley LLP;